"Ibrutinib-resistant TMD8 cells had higher BCL2 gene expression and increased sensitivity to ABT-199 a BCL-2 inhibitor. Consistently clinical samples from ABC-DLBCL patients who experienced poorer response to ibrutinib had higher BCL2 gene expression. We further demonstrated synergistic growth suppression by ibrutinib and ABT-199 in multiple ABC-DLBCL GCB-DLBCL and follicular lymphoma cell lines."xsd:string